General Partner, Frazier Healthcare Partners
Jamie is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team, and has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies.
Jamie has led and served as a board member for many of Frazier’s successful life sciences investments, including Acerta Pharma (sold to AstraZeneca), Calistoga Pharmaceuticals (co-founder, sold to Gilead Sciences), and Incline (co-founder, sold to The Medicines Company). He currently represents Frazier on the boards of Alcresta, Allena Pharmaceuticals, Alpine Immune Sciences, AnaptysBio (NASDAQ: ANAB), Aptinyx, Entasis Therapeutics, and Millendo Therapeutics. He is a board observer for Gritstone Oncology.
Prior to joining Frazier, Jamie ran Millennium San Francisco (formerly COR Therapeutics).
Jamie received his M.D. and Ph.D. in Biophysics from Stanford University and a B.S. from the University of Michigan.